Filing Details
- Accession Number:
- 0001567619-20-012387
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-18 18:03:29
- Reporting Period:
- 2020-06-16
- Accepted Time:
- 2020-06-18 18:03:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1676725 | Ideaya Biosciences Inc. | IDYA | Pharmaceutical Preparations (2834) | 474268251 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1777413 | Mark Lackner | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | Svp, Head Of Biology | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-06-16 | 3,887 | $4.62 | 3,887 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-06-16 | 2,863 | $6.98 | 6,750 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-06-16 | 6,750 | $14.93 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-06-17 | 373 | $4.62 | 373 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-06-17 | 373 | $19.91 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-06-16 | 3,887 | $0.00 | 3,887 | $4.62 |
| Common Stock | Stock Option (right to buy) | Disposition | 2020-06-16 | 2,863 | $0.00 | 2,863 | $6.98 |
| Common Stock | Stock Option (right to buy) | Disposition | 2020-06-17 | 373 | $0.00 | 373 | $4.62 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 62,510 | 2028-06-20 | No | 4 | M | Direct | |
| 36,137 | 2028-12-11 | No | 4 | M | Direct | |
| 62,137 | 2028-06-20 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $14.84 to $15.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 25% of the shares subject to the option vest on the first anniversary measured from May 31, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- This transaction was executed in multiple trades in prices ranging from $19.84 to $19.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
